Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)

NCT06305286 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG: Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy

Sponsor

University of Chicago

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]